Investor Alert

Sept. 3, 2021, 11:16 a.m. EDT

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Forte Biosciences, Inc. (FBRX) Investigation

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Forte Biosciences Inc. (FBRX)

or Cancel Already have a watchlist? Log In

September 03, 2021 (ACCESSWIRE via COMTEX) -- NEW YORK, NY / ACCESSWIRE / September 3, 2021 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Forte Biosciences, Inc. ("Forte" or the "Company") /zigman2/quotes/210207744/composite FBRX +12.56% . Investors who purchased Forte sharesare encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/fbrx .

Image: https://www.accesswire.com/users/newswire/images/662735/image.png

The investigation concerns whether Forte and certain of its officers and/or directors have violated federal securities laws.

On September 2, 2021, post-market, Forte issued a press release "announc[ing] that topline data from its Phase 2 clinical trial of FB-401 for the treatment of atopic dermatitis failed to meet statistical significance for the primary endpoint of EASI-50 (the proportion of patients with at least a 50% improvement in atopic dermatitis disease severity as measure by EASI)." On this news, Forte's stock price fell sharply during intraday trading on September 3, 2021.

If you are aware of any facts relating to this investigation, or purchased Forte shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/fbrx . You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.


Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Yael Nathanson

212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

View source version on accesswire.com:



Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

Copyright 2021 ACCESSWIRE

US : U.S.: Nasdaq
$ 1.21
+0.14 +12.56%
Volume: 464,287
May 17, 2022 4:00p
P/E Ratio
Dividend Yield
Market Cap
$15.87 million
Rev. per Employee

This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.